Small Cap Feast

22th June 2023

Dish of the day
No Joiners today
Off the menu
No leavers today
 
Dish Of The Day:

Joiners: 
No joiners today.

Leavers: 
Industrials REIT has left the Premium Segment of London Stock Exchange. 



What’s Cooking In The IPO Kitchen?

Praetura Growth VCT plc, a newly established VCT announces its intention to float on the Main Market of the London Stock Exchange. The Company will provide growth funding to scalable businesses predominantly based in the North of England, across a range of sectors including technology and healthcare. The Company will be managed by Praetura Ventures Limited, a venture capital and EIS business associated with the wider Praetura Group, a Manchester based venture capital investor and small business lender. The Company is targeting to raise £10m at 1 pence per share, via an offer for subscription. The Directors will have the option to utilise an over-allotment facility that will allow the Company to issue a further 10m Ordinary Shares under the Offer.

CAB Payments Holdings Limited a market lender to business to business (B2B) cross-border payments and foreign exchange, specialising in emerging markets intends to join the Premium Segment of the Main Market. The Group announced revenues of £41.3m for the three months ended 31 March 2023 with the YTD adjusted EBITDA margin at 64%. The Offer is expected to comprise a secondary sell-down of existing ordinary shares by Merlin Midco Limited (a wholly owned subsidiary of Helios Investors III, L.P. and Helios Investors III (A), L.P.) It is rumoured to be valued at between £800m and £1bn with Admission currently expected to occur in July 2023.


Breakfast Buffet

Artisanal Spirits Company 92.5p £64.7m (ART.L)
The owner of The Scotch Malt Whisky Society (SMWS), the curator and provider of premium single cask Scotch malt whisky and other spirits for sale primarily online to a discerning global membership, announces that SMWS won a record haul of five Gold medals and one Silver in the International Spirits Challenge, which promotes outstanding quality spirits from across the globe and receives thousands of entries from over 70 countries worldwide. The Company’s Gold award-winning entries included Cask No. 36.193 Juggling Oranges in a Humidor and Cask No. 94.31 Ice Cream by Candlelight. The accolade is recognition of the Company’s global strategy, plan and in-market delivery in 2022.

EQTEC 0.173p £20.2m (EQT.L)
The technology innovator powering distributed, decarbonised, new energy infrastructure through its waste-to-value solutions for hydrogen, biofuels, and energy generation, confirms that its Market Development Centre (MDC) in Gallina, near Castiglione d'Orcia, Tuscany, Italy, completed handover protocols and transfer of plant operations to EQTEC Italia MDC srl. It is the first of EQTEC's MDCs to be operational. Additionally, Italia MDC is pursuing refinance of the plant asset by an Italian bank, which is expected to complete during Summer 2023.

Fadel Partners 147p £29.4m (FADL.L)
The brand compliance and rights and royalty management software provider, announces its results for the year ended 31 December 2022. Revenue was up 10% to $13.2m (2021: $12.0m). Recurring revenue increased 34% to $8.7m (2021: $6.5m) reflecting the first full year of contribution from IDS of £1.1m ($1.3m). EBITDA loss was $1.5m (2021: $0.93m in EBITDA profit), due to the increased expenditure. Following the IPO in April 2023, cash balance exceeded $10.0m. Trading in FY23 has been in line with expectations and, with a growing pipeline of prospective clients.

Firering Strategic Minerals 7.25p £6.5m (FRG.L)
The exploration company focusing on critical minerals, reports the definition of multiple lithium in soil anomalies and a planned auger drilling programme following the large-scale Phase II soil sampling programme at the Atex Lithium-Tantalum Project in Côte d'Ivoire. Phase II Programme was undertaken in conjunction with Ricca Resources Limited, an Australian diversified minerals company. Several lithium in soil anomalies occur adjacent to and along similar orientations to the Spodumene Hill lithium occurrence where previous drilling returned significant intersections, including an oblique intersection with an apparent width of 64m at 1.24% Li2O and 25m at 1.39% Li2O. Pending results of the Phase I auger programme, further auger infill drilling on a nominal 80m x 20m grid along the defined pegmatite trends planned to define targets ahead of deeper drilling below the depth of weathering for mineralisation potential.

Good Energy Group 175p £29.5m (GOOD.L)
The renewable electricity and energy services provider, announces that it has acquired the entire issued share capital of Wessex EcoEnergy Limited, a UK based solar installation business, on a debt free, cash free basis for an initial consideration of £2.5m. Building on its acquisition of Igloo Works in December 2022, this acquisition represents a further milestone in delivering on Good Energy's strategy to expand its capability in decentralised energy services, complementing its established energy supply business and heat pump installation capability. It also supports Good Energy's ambition to help one million customers by 2025.

IOG plc 4.35p £22.8m (IOG.L)
The developer and producer of indigenous offshore gas via co-owned Saturn Banks production infrastructure, confirms that bondholders controlling 72.8% of the Voting Bonds (representing 100% of the votes casted) have now voted in favour of the proposed Bond amendments as laid out in the RNS of Friday 16th June. The proposed short-term amendments include the waiver of minimum Interest Cover Ratio requirement, the deferral of interest payment date from 20 June 2023 to 31 July 2023 and the waiver of cross-default until 31 July 2023 regarding the subordinated LOG convertible loan note.

Longboat Energy 21.5p £12.2m (LBE.L)
The emerging full-cycle E&P company provides an update on the creation of Longboat JAPEX Norge AS (the Joint Venture). The Norwegian Ministry of Petroleum and Energy has given its approval to the formation of the Joint Venture. Completion of the transaction is now expected to occur in the first half of July 2023. In May 2023, the Company announced that agreement had been reached with Japan Petroleum Exploration Co., Ltd (JAPEX) to make a significant investment into its Norwegian subsidiary, Longboat Energy Norge AS (Longboat Norge), to form a joint venture. Under this agreement, JAPEX will invest in cash of up to US$50m for 49.9% of Longboat Norge and provide the Joint Venture with a US$100m Acquisition Financing Facility to finance acquisitions and associated development costs.

Poolbeg Pharma* 8.4p £42.0m (POLB.L)
The clinical-stage biopharma company focusing on infectious and other prevalent diseases with high unmet medical needs, announces an update on its Oral Vaccine Programme following the award of non-dilutive grant funding by the Irish Government's Disruptive Technologies Innovation Fund (DTIF) in November 2022, as part of the Poolbeg led EncOVac Consortium. Having finalised the research plan and all consortium members completing the Consortium and Grant Agreements, the EncOVac Consortium is now entering the next phase to commence the validation of the encapsulation process. The validation is expected to complete in H2 2023. Poolbeg's Oral Vaccine Programme will possess the capability to generate vaccines for a wide range of diseases and represents a significant commercial opportunity.

Roquefort Therapeutics* 7.13p £9.2m (ROQ.L)
The biotech company focused on developing first-in-class medicines in the high value and high growth oncology market, announces the progress of its anti-cancer RNA oligonucleotide program targeting Midkine expressing cancers producing >90% in vitro efficacy (at the mRNA level) in human liver and neuroblastoma cancer cells. The Company's anti-cancer RNA oligonucleotide program will now progress into in vivo studies which are planned to complete in Q4 2023. Liver cancer incidences are forecast to increase to one million new patients per year by 2025. The 5-year survival rate is only 21% because the existing medicines have limited effect. This type of cancer is a key focus for Roquefort’s portfolio of Midkine targeting medicines including antibodies, mRNA and the anti-sense oligonucleotides.

Volex Group 277.75p £443.5m (VLX.L)
The integrated manufacturer of critical power and data transmission products, announces that it has agreed to acquire 100% of Murat Ticaret Kablo Sanayi A.Ş. (Murat Ticaret), a manufacturer of complex wire harnesses headquartered in Turkey for a total consideration of up to approx. EUR178m, together with a placing and retail offer to raise gross proceeds of approximately £60m in aggregate. The enterprise value of EUR178m implies an acquisition multiple of 5.3x Murat Ticaret's CY2022 EBITDA.

22 June 2023
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram